PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-19.78%
Negative net income growth while AVXL stands at 10.36%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
2.78%
D&A growth of 2.78% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
37.14%
SBC growth while AVXL is negative at -26.44%. John Neff would see competitor possibly controlling share issuance more tightly.
172.06%
Well above AVXL's 336.28% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
172.06%
Lower 'other working capital' growth vs. AVXL's 445.45%. David Dodd would see fewer unexpected short-term demands on cash.
-10743.19%
Both negative yoy, with AVXL at -36.72%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-10.71%
Negative yoy CFO while AVXL is 23.16%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.75%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.18%
Negative yoy issuance while AVXL is 17.34%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.